Form 4: Myriad Genetics COO Executes Tax-Related Share Withholding

Myriad Genetics Chief Operating Officer Mark Verratti had 1,069 shares withheld to satisfy tax obligations upon the vesting of restricted stock units.

Summary

• Mark Verratti, Chief Operating Officer of Myriad Genetics, Inc. (MYGN), reported a transaction involving the withholding of 1,069 shares of common stock.
• The transaction occurred on April 14, 2026, at a price of $4.91 per share.
• The withholding was executed to satisfy tax obligations related to the vesting of previously granted restricted stock units.
• Following this transaction, the reporting person maintains direct beneficial ownership of 629,646 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax-withholding transaction rather than a market-driven trade.

Positives

• The transaction is a routine administrative action related to tax compliance rather than a discretionary sale of shares.
• The reporting person retains a significant equity stake of 629,646 shares, indicating continued alignment with shareholder interests.

Negatives

• None identified; this is a standard tax-withholding event.

Risks

• None identified; this filing pertains to routine equity compensation management.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure for executive compensation and does not reflect a change in corporate strategy or market outlook.

Comparison to Industry Standards

• The transaction follows standard industry practices for executive equity compensation and tax withholding protocols.
• The reporting person's continued high level of ownership is consistent with typical executive retention structures in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a non-discretionary tax settlement.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Trading, Tax Withholding, Equity Compensation